NeoGenomics say-on-pay fails at 2022 annual meeting; directors elected

NEOGENOMICS INC

Say-on-pay received 30.6% for vs 68.9% against (advisory, non-binding).
Director Michael A. Kelly received 57.9M for, 39.1M withheld (40%).
Stockholders approved third amendment of employee stock purchase plan (99.6% for).
Ratification of independent auditor received 99.8% for (106.0M shares).
106.3M shares present (85.6% of outstanding) at June 2, 2022 meeting.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.